Y-mAbs Therapeutics Plans Conference Call for Q3 Results
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a leading biopharmaceutical company, has announced an important upcoming conference call. The call will take place on November 8, 2024, prior to the market opening. This event aims to provide investors and stakeholders with insights into their financial and operational performance for the third quarter of 2024.
Details of the Upcoming Conference Call
During this conference call, Y-mAbs will delve into its financial results and provide updates on operations. The call is slated for 8:00 a.m. EST, allowing participants to join and learn more about the company’s ongoing progress and future strategies.
How to Participate
Investors interested in joining the call can dial in using the following numbers: for domestic listeners, the number is (877) 407-0792, while international callers can reach the conference at (201) 689-8263. This is an excellent opportunity for stakeholders to hear directly from Y-mAbs leadership about the company’s trajectory and plans.
About Y-mAbs Therapeutics, Inc.
Y-mAbs is recognized for its commitment to developing innovative therapies to address cancer treatment. The firm specializes in radioimmunotherapy and antibody-based drugs, harnessing cutting-edge technology to advance treatment options. One of their flagship products, DANYELZA® (naxitamab-gqgk), has made significant strides as the first FDA-approved therapy for patients with relapsed or refractory high-risk neuroblastoma.
Innovative Technology and Products
The company’s pioneering technologies, including the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), exemplify its dedication to transforming cancer care. By utilizing these innovative platforms, Y-mAbs continues to expand its product pipeline, focusing on therapies that offer hope to patients facing serious challenges in treatment.
Investor Relations and Company Information
For those seeking more information about the company, Y-mAbs maintains a robust investor relations program. The VP, Head of Investor Relations, Courtney Dugan, is readily available for inquiries. Interested parties can reach out via email at cdu@ymabs.com. This ensures that investors have access to the latest updates and valuable insights about the company's performance and future endeavors.
Commitment to Transparency
Y-mAbs prides itself on transparency and regular communication with its stakeholders. The upcoming conference call is a testament to this commitment, allowing for an open dialog regarding its financial health and the innovative steps being taken in the fight against cancer.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call is intended to share Y-mAbs' third quarter 2024 financial and operational results with investors and stakeholders.
When will Y-mAbs hold the conference call?
The call is scheduled for November 8, 2024, at 8:00 a.m. EST.
How can investors join the conference call?
Investors can participate by dialing (877) 407-0792 for domestic calls and (201) 689-8263 for international calls.
What products are highlighted by Y-mAbs?
Y-mAbs highlights its anti-GD2 therapy DANYELZA®, which is FDA-approved for treating relapsed or refractory high-risk neuroblastoma.
Who can investors contact for more information?
Investors can contact Courtney Dugan, VP of Investor Relations, via email at cdu@ymabs.com for further inquiries.